In our evaluation of different clinical parameters usually included in prognostic/predictive models of metastatic prostate cancer (36) time to development of castration resistance and Hb levels were confirmed as independent prognostic factors for OS, findings in line with the results of previous studies of mCRPC patients treated with enzalutamide (37). Here, GSTM1 is linked to metastatic prostate carcinoma.